May 24,2023

Tennessee Receives Largest BVL Grant to Deploy MyndVR Across All TN State Veteran Homes

MyndVR secures a significant BVL grant to deploy virtual reality glasses across Tennessee State Veteran Homes, benefiting over 10,000 veterans. The grant, in collaboration with the National Association of State Veteran's Homes, marks a milestone in providing innovative digital therapeutic experiences. MyndVR's immersive glasses offer emotional, cognitive, and physical benefits, improving healthcare outcomes while reducing costs. This advancement aligns with the bipartisan Access to Prescription Digital Therapeutics Act, recognizing the necessity of scalable and evidence-based digital therapeutics.

FUNDING GRANT

#virtual reality

View Analyst & Ambassador Comments
Go to original news
May 02,2023

DarioHealth Announces $14.3 Million Private Placement

DarioHealth Corp. announced the pricing of a $14.3 million private placement of convertible preferred stock, priced at the market under Nasdaq rules, with significant participation by select members of leadership, the Board and existing investors.

FUNDING POST-IPO EQUITY
View Analyst & Ambassador Comments
Go to original news
May 02,2023

Hygieia Extends Series B Round to $22 Million with Participation from Strategic Investors

Hygieia, a digital therapeutics company for insulin therapy, is extending its Series B funding round to $22 million with a lead investment from Firstime Ventures and additional investment from two strategic partners.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Apr 06,2023

Better Therapeutics Announces $6.5M Private Placement

Better Therapeutics, a prescription digital therapeutics (PDT) firm, has announced a $6.5m private placement of its common stock at $0.825 per share. The financing will support the execution of key milestones, extending the company's runway through the date of potential FDA marketing authorization of BT-001 and the completion of other strategic initiatives. This financing is one element of the three-tiered strategy discussed on the company’s most recent earnings call. Chardan and Brookline Capital Markets are co-placement agents for the private placement. The securities are being sold in a private placement and have not been registered under the Securities Act of 1933

FUNDING POST-IPO EQUITY
View Analyst & Ambassador Comments
Go to original news
Mar 22,2023

Cognito beams up $73M for study of light-and-sound neuromod therapy to treat Alzheimer's

Cognito Therapeutics has secured $73 million in a series B funding round, led by FoundersX Ventures, to advance its light-and-sound neuromodulation headset technology, which is being studied for its potential to treat Alzheimer's disease. The headset combines personalized gamma-frequency light and audio stimulation to stimulate gamma oscillations, a mechanism that promotes stronger brain connections and efficient removal of neuron-destroying proteins. Cognito's approach differs from other Alzheimer's treatments that target proteins like beta-amyloid and tau. The funding will support a pivotal study of the technology, which began last month, and expanding the team. Early trial results have shown promise

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Mar 22,2023

Digital therapeutics startup Mindset Health scores $12M in Series A funding

Australian digital therapeutics startup Mindset Health has raised $12m in a series A funding round to develop and launch new hypnosis-based DTx apps. The round was led by King River Capital and included participation from Tenmile, Yard Ventures, WordPress founder Matt Mullenweg, and Linktree founders Anthony Zaccaria and Nick Humphreys. Mindset Health's existing range of DTx apps address health conditions such as irritable bowel syndrome, menopause and smoking cessation. The company plans to use the new funds to develop apps for anxiety and depression, sleep, and chronic pain, and to strengthen its existing apps with additional features and personalisation

FUNDING SERIES A
View Analyst & Ambassador Comments
Go to original news
May 03,2023

Dexcom Prices Upsized Offering of $1.1 Billion of 0.375% Convertible Senior Notes Due 2028

DexCom, Inc. announced today the pricing of its offering of $1.1 billion aggregate principal amount of 0.375% Convertible Senior Notes due 2028 (the "notes") in a private placement. The notes will be senior, unsecured obligations of Dexcom, and will bear interest at a rate of 0.375% per year, payable semi-annually in arrears on May 15 and November 15 of each year, beginning on November 15, 2023.

FUNDING POST-IPO DEBT
View Analyst & Ambassador Comments
Go to original news
May 02,2023

DarioHealth Announces $14.3 Million Private Placement

DarioHealth Corp. announced the pricing of a $14.3 million private placement of convertible preferred stock, priced at the market under Nasdaq rules, with significant participation by select members of leadership, the Board and existing investors.

FUNDING POST-IPO EQUITY
View Analyst & Ambassador Comments
Go to original news
May 02,2023

Hygieia Extends Series B Round to $22 Million with Participation from Strategic Investors

Hygieia, a digital therapeutics company for insulin therapy, is extending its Series B funding round to $22 million with a lead investment from Firstime Ventures and additional investment from two strategic partners.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Apr 03,2023

Wellth raises $20M for health app with financial rewards

Wellth, a digital health startup that offers small financial rewards for completing health-related tasks, scooped up $20 million in Series B funding. Wellth works with insurers, providers and employers to offer an app that reminds users about daily health behaviors, like taking medications or monitoring blood glucose. When patients take a photo confirming they've completed tasks, they receive small financial incentives. The company includes services for mental health concerns, cardiovascular disease, heart failure, diabetes, cancer, chronic kidney disease and COPD or asthma.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Subscribe to FUNDING